Analyst firms · H.C. Wainwright · ANAB
H.C. Wainwright ANAB price target and rating history
AnaptysBio Inc. (ANAB) · Health Care
H.C. Wainwright rates AnaptysBio Inc. (ANAB) Buy with a $95 price target, as of its latest action on Jun 10, 2026. It has published 6 rating actions on ANAB since March 2022, including 1 upgrade and 1 downgrade.
- Current rating
- Buy
- Price target
- $95
- Median target, all firms
- Too few
- Actions on ANAB
- 6
H.C. Wainwright price target on ANAB
Every H.C. Wainwright rating on ANAB
- Jun 10, 2026
- Jun 4, 2025
- Dec 11, 2024
- Jul 22, 2024
- Sep 19, 2022
- Mar 8, 2022
How other firms rate ANAB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Buy | $95 | Jun 10, 2026 |
| UBS | Buy | $70 | Jan 7, 2026 |
Questions about H.C. Wainwright and ANAB
- What is H.C. Wainwright's price target for ANAB?
- H.C. Wainwright's latest stated price target for AnaptysBio Inc. (ANAB) is $95, from its action on Jun 10, 2026.
- What is H.C. Wainwright's rating on ANAB?
- H.C. Wainwright rates ANAB Buy, a bullish rating, as of Jun 10, 2026.
- When did H.C. Wainwright last change its view on ANAB?
- On Jun 10, 2026, H.C. Wainwright resumes coverage at Buy, price target $95.
All H.C. Wainwright ratingsANAB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.